In competition assays, CCNI‐targeting sgRNAs similarly sensitized AML cells to AG636 treatment, whereas CDK5R1 knockout had no effect (Figs 7B and EV5B). This evidence concerns the gene CDK5R1 and acute myeloid leukemia.